

CURRICULUM VITAE

Mikhail I. Shtivelband, M.D., Ph.D.

Ironwood Cancer & Research Centers a division of Ironwood Physicians, PC

Current Address:

Ironwood Cancer & Research Centers, PC
695 South Dobson Road
Chandler, Arizona 85224
480-821-2838

Citizenship: USA

Active Licensures: Arizona: 32733
Texas: L6366

Specialty Boards: **2000** Diplomat, American Board of Internal
Medicine
2003 Diplomat, Subspecialty Board in Medical
Oncology
2003 Diplomat, Subspecialty Board in
Hematology

Education: **1991 – M.D.**
Chelyabinsk State Medical Institute
Chelyabinsk, Russia
1994 – Ph.D.
Chelyabinsk, State Medical Institute
Chelyabinsk, Russia

Post Graduate Training and Experience

2003 - 2004 Research Fellow – Vascular Biology
Department of Hematology
University of Texas, Health Science Center

Post Graduate Training and Experience (continued)

2000 – 2003 Fellowship – Hematology/Oncology

University of Texas Health Science Center
University of Texas M.D. Anderson Cancer Center
Houston, Texas

1997 – 2000 Residency – Internal Medicine
St. Vincent's Medical Center of Columbia
College of Physicians and Surgeons
Bridgeport, Connecticut

1995 – 1997 Volunteer Medical Assistant
Internal Medicine Office
Princeton, New Jersey

1992 – 1995 Staff Physician
Department of Hematology
Chelyabinsk Regional Hospital
Chelyabinsk, Russia

1991 – 1992 Internship – Internal Medicine
Chelyabinsk Regional Hospital
Chelyabinsk, Russia

Honors and Awards

ICU Resident of the Year Award (2000), St. Vincent's Medical Center,
Bridgeport, Connecticut

Resident Teacher Award (2000), St Vincent's Medical Center,
Bridgeport, Connecticut

Diploma with Distinction and Honors for academic achievements and
research work, Chelyabinsk Medical Institute, Chelyabinsk,
Russia

Gold Medal for academic achievement in High School (1985)

Bibliography

Publications:

1. McGary, E.C., Heimberger, A.B. Ruiz, M., Wang, H., Fuller, G.N., Mills, L., Thomas, G., **Shtivelband, M** and Bar-Eli, M. *Loss of the AP-2a Transcription Factor is Associated with the Grade of Human Gliomas.* (Submitted, Journal of Clinical Oncology)
2. McGary, E.C., Onn, A., Mills, L., Heimberger, A.G., Thomas, G., **Shtivelband, M.** and Bar-Eil, M. *The Novel Tyrosine Kinase Inhibitor STI571 Inhibits PDGF Phosphorylation on Melanoma Cells but does no Effect Tumorigenicity in Vivo* (Submitted, Melanoma Research)
3. McGary, E.C., Heimberger, A.B., Mills, L., Weber, K., Thomas, G., **Shtivelband, M.**, Chelouche Lev, D., and Bar-Eli, M. *A Fully Human Anti-MCAM/MUC18 Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells in Vivo,* (Clinical Cancer Research)
4. **M.I. Shtivelband,** H.S. Juneja, Sang Lee and Kenneth K. Wu: *Aspirin and salicylate inhibit colon cancer medium and VEGF induced endothelial tube formation via suppression of endothelial cell cyclooxygenase-2 expression.* Journal of Thrombosis and Hemostasis, January 2003
5. W.G. Deng, M.A. Saunders, D.W. Gilroy, X.Z. He, Y. Zhu, **Mikhail I. Shtivelband,** Ke-He Ruan, and K.D. Wu: *Purification and characterization of cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts:* FASEB Journal. 16(10):1286-8, August 2002
6. Iarovinsky B.G., Zurochka A.V., Ebert, L.I., **Shtivelband, MI,** Popov, G.K.: *Status of the regulatory function of neutrophils in patients with atopic dermatitis.* [Russian]. BIULLETEN Shtivelband, M.I.
7. **M. Shtivelband** *Correction of myeloid suppression in the toxic phase of burn disease with the plasma of animals that have survived thermal injury.* Dissertation for the degree of Candidate of Medical Sciences. [Russian]. Chelyabinsk Medical Institute. Chelyabinsk, Russia. November 1994.
8. Popov, G.K., Pochinskij A.G., **Shtivelband, M.I.:** *A device for the mechanical division of the bone marrow in the tubular bones into axial and cortical zones.* [Russian]. Patologicheskaja Fiziologia I Eksperimentalnaia Terapija. (3): 48-9, 1991 May – June.

Published Abstracts

W.G. Deng, **M. Shtivelband**, and K.K. Wu: *Control of cancer-induced angiogenesis by an endogenous factor*. American Society of Hematology Annual Meeting, Philadelphia, Pennsylvania, December 6-10, Blood, 100(11): 682a, Nov. 2002

M. Shtivelband, Harinder Juneja, Sang, Lee and K.K. Wu: *Suppression of cancer medium and VEGF-induced endothelial tube formation by aspirin and sodium salicylate*. American Society of Hematology Annual Meeting. Philadelphia, Pennsylvania, December 6-10, Blood, 100 (11): 683a, 2002 Nov.

Iarovinsky B.G., Zurochka A. **Shtivelband M.**, Shelgaev N., Vazhenin A.: *Colony-and cluster-formation of CFU-GM in patients with Psoriasis and Atopic Dermatitis in exacerbation*. [Russian]. Materials of II Conference of Dermatologist of Siberia. Novosibirsk. Russia. October 15-16, 1997

Iarovinsky B.G., Zurochka A.V., **Shtivelband, M.I.**, Kataev I, Vazhenin A., Kornilova N.: *Regulation of phagocytic chain of immunity in patients with atopic dermatitis and attempts of correction with electro-acupuncture therapy*. [Russian]. Materials of First National Conference of Russian Association of Allergologist and Clinical Immunologists. Moscow. Russia. January 28-31, 1997.

Iarovinsky B.G., Zurochka A.V., **Shtivelband, M.**, Ebert, L.: *Rehabilitative influence of electro-acupuncture on function of phagocytes in patients with Atopic Dermatitis*. 5th International Expert Forum of Immunotherapy and Gene Therapy. Jerusalem. Israel. June 1996.

Dolgushin, I., Iarovinsky B.G., Zurochka A.V., **Shtivelband, M.**, Giniatullin R.: *Influence of neutrophils secretory products on immune and nervous system of CBA mice*. The 1995 International Co-conference on Environmental Pollution (ICEP'95) and Neuroimmuno Interactions and Environment (ICONE'95). St. Petersburg, Russia. July 17-24, 1995. Page 105.

Zurochka, A.V., Zhemchugov, V., Iarovinsky, B.G., **Shtivelband, M.**, Rumjantsev, A., Chukichev, A.: *Use of the GM-CSF external chain peptide fragment as colony-stimulating activity in CFU-GM assay in vitro*. Proceedings of the Laboratory Medicine '95 11th IFCC European Congress of Clinical Chemistry. Tampere. Finland. July 2-7, 1995: 414

Iarovinsky B.G., Zurochka, A.V., **Shtivelband, M.I.**, Chukichev, A.V.: *Study of the regulatory function of neutrophils from patients with Atopic Dermatitis*. Protocols of the First International Congress of Immunorehabilitation. Dagomys. Russia. International Journal of Immunorehabilitation. 1994. Number 1 – Supplement: 381.

Iarovinsky, B.G., Zurochka, A.V., **Shtivelband, M.I.**, Chukichev, A.V.: *Phagocytic chain of immunity in patients with atopic dermatitis*. [Russian]. Proceedings of the Conference of Dermatologist of Urals, Siberia and Far East. Ekaterinburg. Russia. May 12-13, 1994.

RESEARCH PROTOCOLS – PRINCIPAL INVESTIGATOR

1. **Amgen Protocol 20060136**: A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer. (2007 -)
2. **Astra Zeneca Protocol D4200C00036**: A Phase III, Randomized, Double-Blinded, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-Cancer Therapy. (2007 – 2008)
3. **Amgen Protocol 20060362**: An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer (2008 -)
4. **Pfizer Protocol A6181104**: A Randomized, Phase 2B Study of Sunitinib Plus Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX as First-Line Treatment In Patients with Metastatic Colorectal Cancer (2008 -)
5. **Sanofi-Aventis Protocol**: A Multicenter, Randomized, Double-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-Line Treatment of Patients with Metastatic Colorectal Cancer Treated with Oxaliplatin/5-FU/LV (2007 -)
6. **Novacea Protocol 011-007**: A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2) (2007)